FDA grants Fast Track for PMN310; ATM program terminated after minimal sales

ProMIS Neurosciences Inc.

FDA granted Fast Track Designation to PMN310 for Alzheimer's disease.
DSMB approved dose escalation to second 10 mg/kg cohort in Phase 1b trial (May 2025).
No cases of ARIA (brain swelling/microhemorrhages) observed as of July 21, 2025.
ATM program with BTIG terminated; only $190,274 raised of $25M available (75,862 shares sold).
No termination penalties; no further shares will be sold under the program.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.